D
Dean Thomas Jorstad
Researcher at Children's Hospital of Wisconsin
Publications - 3
Citations - 378
Dean Thomas Jorstad is an academic researcher from Children's Hospital of Wisconsin. The author has contributed to research in topics: Survival rate & Imatinib. The author has an hindex of 2, co-authored 3 publications receiving 317 citations.
Papers
More filters
Journal ArticleDOI
Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031.
Kirk R. Schultz,Andrew J. Carroll,Nyla A. Heerema,W P Bowman,Alexander Aledo,William B. Slayton,H N Sather,Meenakshi Devidas,H. W. Zheng,Stella M. Davies,Paul S. Gaynon,Michael E. Trigg,Robert Rutledge,Dean Thomas Jorstad,Naomi J. Winick,Michael J. Borowitz,Stephen P. Hunger,William L. Carroll,Bruce M. Camitta +18 more
TL;DR: Longer-term follow-up confirms the initial observation of substantially good outcomes for children and adolescents with Ph+ ALL treated with imatinib plus intensive chemotherapy with no advantage for allogeneic BMT.
Journal ArticleDOI
Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study.
Julio C. Barredo,Caroline Hastings,Xiamin Lu,F. Meenakshi Devidas,Yichen Chen,Daniel Armstrong,Naomi J. Winick,Brent L. Wood,Rochelle Yanofsky,Mignon L. Loh,Julie M. Gastier-Foster,Dean Thomas Jorstad,Robert B Marcus,Kim Ritchey,William L. Carrol,Stephen P. Hunger +15 more
TL;DR: This study aimed to improve outcome in patients with ITR of B‐cell ALL occurring after 18 months of first clinical remission using intensive systemic chemotherapy and to decrease long‐term sequelae by limiting use of testicular radiation.
Journal ArticleDOI
A phase II study of amifostine in children with myelodysplastic syndrome: A report from the Children's Oncology Group study (AAML0121)†‡
Prasad Mathew,Robert B. Gerbing,Todd A. Alonzo,Tanya Wallas,Jerald Z. Gong,Rama Jasty,Dean Thomas Jorstad,Susana C. Raimondi,Cathy M. Chavez,Nancy Eisenberg,Betsy A. Hirsch,Alan S. Gamis,Franklin O. Smith,Robert J. Arceci +13 more
TL;DR: The study was closed after being open for 2 years due to slow accrual and the role of amifostine in pediatric MDS was not known at the time of study.